Followers | 27 |
Posts | 4410 |
Boards Moderated | 0 |
Alias Born | 01/03/2017 |

Friday, May 28, 2021 11:12:35 AM
Recent OCGN News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2025 01:45:30 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2025 01:43:21 PM
- Ocugen Provides Business Update with First Quarter 2025 Financial Results • GlobeNewswire Inc. • 05/09/2025 12:01:07 PM
- Ocugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial Results • GlobeNewswire Inc. • 05/02/2025 12:00:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/01/2025 01:22:51 PM
- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2025 Annual Meeting and Retina World Congress • GlobeNewswire Inc. • 04/29/2025 11:30:40 AM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/25/2025 08:59:03 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/25/2025 08:58:06 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/25/2025 08:56:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/25/2025 08:45:33 PM
- Ocugen to Present at the 2025 Cell & Gene Meeting on the Med • GlobeNewswire Inc. • 04/08/2025 12:02:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/04/2025 01:23:08 PM
- Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema • GlobeNewswire Inc. • 03/18/2025 12:02:09 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/05/2025 09:30:52 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/05/2025 02:42:59 PM
- Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results • GlobeNewswire Inc. • 03/05/2025 12:02:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2025 11:59:40 AM
- Ocugen Announces Positive Opinion of EMA’s Committee for Advanced Therapies for ATMP Classification for Novel Modifier Gene Therapy Candidate OCU410 for Geographic Atrophy and OCU410ST for Stargardt Disease • GlobeNewswire Inc. • 03/03/2025 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/03/2025 01:43:25 PM
- Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease • GlobeNewswire Inc. • 02/27/2025 01:46:50 PM
- Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results • GlobeNewswire Inc. • 02/21/2025 01:00:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/12/2025 01:39:20 PM
- Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration • GlobeNewswire Inc. • 02/12/2025 12:42:23 PM
Lingerie Fighting Championships Coming to the UK for July 4 & 6 Events • BOTY • May 19, 2025 10:00 AM
VAYK Projects to Report Over $400K Q1 Revenue • VAYK • May 15, 2025 9:00 AM
Veri Medtech (VRHI) Reaches $100 Million Revenue Milestone • VRHI • May 15, 2025 8:00 AM
Cannabix Enters Sales Distribution Agreement with Australian Distributor for BreathLogix Autonomous Alcohol Breathalyzer • BLO • May 14, 2025 8:51 AM
North Bay Resources Announces Resource Estimate of 474,000 ounces at Fran Gold Project, British Columbia • NBRI • May 13, 2025 9:58 AM
UC Asset Filed for Public Offering of 8% Dividend Preferred Units • UCASU • May 12, 2025 9:55 AM